AIDS: Women comprise 45 percent of new HIV infections, but account for only 9 to 20 percent of clinical research participants. Hoffmann-La Roche is conducting a study to evaluate potential differences in response to antiretroviral drug therapy based on gender. The study will enroll 60 women and 20 men, all HIV-positive. It will compare the participants' responses to Saquinavir (Fortovase) in combination with two nucleoside reverse transcriptase inhibitors. Researchers will look at immunologic measures including CD4 cell count and viral suppression. The trial will also evaluate the efficacy of Saquinavir and oral contraceptives when used together. Contact information is provided.